2bind and Creoptix sign technology-service partnership
Zurich, Switzerland, and Regensburg, Germany, 17 November 2020 – Creoptix and 2bind have signed a technology-service partnership, which enables both parties to continue offering customers the highest quality research tools and help them accelerate their R&D. The collaboration supports 2bind to expand its service portfolio with the innovative WAVEsystem and provides Creoptix with a highly experienced partner as a certified service provider and beta-tester for future technology developments.
2bind is a well-known Contract Research Organization (CRO) in the field of early drug discovery with almost ten years of experience in the market. Its customers will now benefit from the availability of efficient and scalable binding assays based on Creoptix’ proprietary Grating-Coupled Interferometry (GCI) technology, offering accurate kinetic rates and affinity constants for label-free analysis of biomolecular interactions.
Thomas Schubert, CEO of 2bind, commented: “In order to provide tailor-made outsourcing solutions to customers in early drug discovery, 2bind operates a unique portfolio of biophysical methods and assays. With the integration of Creoptix’ innovative GCI technology, we gain another piece in the puzzle to solve our customers’ questions. GCI is superior to traditional label-free technologies, such as Surface Plasmon Resonance (SPR), particularly in characterizing interactions of drug targets with small molecules and fragments. The WAVEsystem can resolve the fastest binding kinetics, has an intrinsically higher accuracy compared to competitor technologies, and can even handle crude reaction mixtures and biofluids like serum and plasma. These features will be very helpful for 2bind’s hit identification and validation projects, both in small molecule- and in fragment-based drug discovery. 2bind is proud to be a certified service provider for Creoptix and we look forward to help boost novel developments with our expertise in biophysics.”
Line Stigen Raquet, CEO of Creoptix, said: “Creoptix and 2bind share a strong commitment to serving customers and helping them achieve scientific breakthroughs. 2bind is an excellent partner for us to continue to innovate and deliver the best high-quality tools for label-free biosensing analysis. I am proud of Creoptix’ track record of building strong and lasting relationships with customers around the world to create win-win partnerships, and this is a fantastic showcase for our capabilities. Early Drug Discovery is a top priority for our business, and the partnership with 2bind will further enable us to drive the expansion of the WAVEsystem in this key market.”
Contact Creoptix
or
Beatrix Benz
beatrix.benz@benz-advisory.com
+41 79 256 77 73
Contact 2bind
Dr. Thomas Schubert
+49 941 200 008 90
About Creoptix
Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and with US offices in the Boston area. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix WAVEsystem provides exceptionally high sensitivity and resolution to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics, and other molecules even in biofluids like undiluted serum or plasma. www.creoptix.com
About 2bind
2bind is a provider of biophysical analytical services with a focus on drug discovery and antibody development headquartered in Regensburg, Germany. 2bind´s mission is to accelerate customer research by developing and preforming high-end, scalable, and cost-efficient assays based on innovative biophysical technologies. 2bind´s customers benefit from expert knowledge in biophysics and the experience of >700 projects with >150 customers. www.2bind.com
